PRESS RELEASE SUMMIT, N.J. & SEATTLE—-Celgene Corporation and Juno Therapeutics, Inc UK medical jpournal . announced today a worldwide collaboration for the development and commercialization of immunotherapies. Both companies will leverage T cell therapeutic strategies to develop treatments for sufferers with tumor and autoimmune illnesses with an initial focus on Chimeric Antigen Receptor Technology and T Cell Receptor technologies. This purchase strengthens Celgene’s placement in the emerging and transformative region of immuno-oncology, said Bob Hugin, CEO and Chairman of Celgene.

Cell Biosciences announces acquisition of Brightwell Technologies Cell Biosciences, Inc. Announced that it has acquired Brightwell Technologies today, Inc. Of Ottawa, Ontario for U approximately.S. $9 million in cash. Brightwell Technologies may be the market innovator in Micro-Circulation Imaging , an analytical technique used to detect contaminants and aggregates in protein-based therapeutics. Because of high interest in protein aggregation expressed by the FDA and various other regulatory agencies, Brightwell’s MFI items have observed widespread adoption by the world’s largest pharmaceutical and biotechnology businesses. Brightwell was founded in 2001 and employs 30 people at its headquarters in Ottawa approximately, Ontario.